Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. (2nd November 2018)

• Record Type: Journal Article
• Authors: Nishio, Masafumi; Ishii, Yoshito; Hashimoto, Yu; Otake, Haruka; Ogashiwa, Tsuyoshi; Tsuda, Saya; Yasuhara, Hisae; Saigusa, Yusuke; Kimura, Hideaki; Maeda, Shin; Kunisaki, Reiko
• Is Part Of: Scandinavian journal of gastroenterology. Volume 53:Number 10/11(2018)
• Page Start: 1236
• Page End: 1244
• Publication Date: 2018-11-02
• Subjects: Ulcerative colitis -- adalimumab -- anti-tumour necrosis factor monoclonal antibodies -- calcineurin inhibitor -- remission -- colectomy -- salvage -- tacrolimus -- cyclosporine; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2018.1511825
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Objective: Calcineurin inhibitors are highly effective in patients with corticosteroid-refractory ulcerative colitis (UC). When therapy with calcineurin inhibitors fails, adalimumab can be considered to avoid colectomy. The efficacy and safety of this sequential alternative salvage therapy remain unknown. Therefore, the present study was performed to investigate the short- and long-term efficacy and safety of adalimumab after failure of calcineurin inhibitors in corticosteroid-refractory UC. Materials and methods : Patients with a corticosteroid-refractory flare of UC who did not respond to calcineurin inhibitors and received continuing salvage therapy with adalimumab were included in this retrospective, observational, single-centre study. The cumulative rates of colectomy were calculated using the Kaplan–Meier method. Clinical remission and response were evaluated based on the Rachmilewitz index. The cumulative rates of colectomy were calculated. Predictive factors for clinical remission and colectomy were identified. In the safety evaluation, any adverse event occurring after the administration of adalimumab was considered. Results: Forty-one patients were enrolled; 78% had extensive colitis and 87% had moderate to severe colitis. Seventeen patients (41%) underwent colectomy during the follow-up period. At week 8, 26, and 52 after adalimumab injection, 27%, 39%, and 32% of patients achieved clinical remission, respectively. The adverse event rate was 17%, including one case of tuberculosis. Conclusions: The efficacy of adalimumab for calcineurin inhibitor-refractory UC was examined for the first time. Treatment with adalimumab avoided the need for colectomy in two-thirds of patients with corticosteroid-refractory UC in whom calcineurin inhibitors had failed. However, attention is needed to avoid adverse events, especially infection.